Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Environmental Toxins Can Cause Parkinson’s Disease Model in Rats

22.06.2004


Scientists have induced a movement disorder in rats that closely resembles Parkinson’s disease in humans. The study, published June 21, 2004, in the online edition of the Annals of Neurology, suggests that natural toxins found in the environment could contribute to the development of this debilitating movement disorder.

The compounds, called proteasome inhibitors, can be produced by bacteria and fungi. Man-made proteasome inhibitors may also find their way into the environment.

"These results suggest that we should determine how widespread these toxins are in the environment, how humans are exposed to them, and how such exposures correlate with the incidence of Parkinson’s disease," said lead author Kevin St. P. McNaught, PhD, of the Mount Sinai School of Medicine in New York City.



Ironically, proteasome inhibitors are currently being used as a treatment for cancer.

Parkinson’s disease afflicts up to a million Americans. Symptoms can include slowness of movement, tremor when at rest, muscle rigidity abnormalities of gait. Parkinson’s symptoms can be traced to the progressive death of nerve cells, most prominently in an area of the brain called the substantia nigra accompanied by a loss of the brain chemical dopamine.

What kills the nerve cells in Parkinson’s is not known, but it is suspected that the majority of cases are related to environmental factors that could include exposure to toxins.

Several animal models of Parkinson’s disease exist, but none recapitulate the features of the disease as closely as the present model, said C. Warren Olanow, M.D., Ph.D., chair of neurology at Mount Sinai, and a co-author of the study.

Proteasomes are responsible for eliminating abnormal proteins from cells, acting like a garbage disposal system. Based on growing evidence that proteasomes are defective in Parkinson’s disease, McNaught and colleagues examined the effects of experimentally interfering with proteasomes in laboratory rats, using both man-made and naturally occurring proteasome inhibitors.

About two weeks after receiving injections of proteasome inhibitors, the rats began to show symptoms similar to Parkinson’s disease, including slowness of movement, rigidity, and tremor. "These symptoms gradually worsened over a period of months, and could be reversed with drugs that are used to treat Parkinson’s patients," said McNaught.

Imaging studies of the living animals’ brains demonstrated changes in a pattern identical to that seen in Parkinson’s disease. Similarly, autopsy studies on the animals’ brains demonstrated a reduction in brain levels of dopamine and nerve cell loss in a pattern that closely resembled Parkinson’s disease.

"We create animal models of a disease for several reasons," said Dr. Olanow. "We can use the model to find underlying mechanisms responsible for the disease, identify targets for drug development, and test any new therapies. Our present model should facilitate accomplishing these goals in Parkinson’s disease."

McNaught notes that epoxomicin, one of the most potent proteasome inhibitors known, is produced by the common actinomycetes bacteria, which is found in soil and well water throughout the world.

"It’s only speculation at this point, but the fact that living in rural areas and drinking well water has been reported to be associated with higher rates of Parkinson’s disease could be related to higher levels of proteasome inhibitors found in these areas" said Dr. Olanow.

Article: “Systemic Exposure to Proteasome Inhibitors Causes a Progressive Model of Parkinson’s Disease,” Kevin St. P. McNaught, Daniel P. Pearl, Anna-Liisa Brownell, and C. Warren Olanow, Annals of Neurology; Published Online: June 21, 2004 (DOI: 10.1002/ana.20186).

The Annals of Neurology, the preeminent neurological journal worldwide, is published by the American Neurological Association, the world’s oldest and most prestigious neurological association. The 1,400 members of the ANA--selected from among the most respected academic neurologists and neuroscientists in North America and other countries--are devoted to furthering the understanding and treatment of nervous system disorders.

ANA | newswise
Further information:
http://www.aneuroa.org

More articles from Studies and Analyses:

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>